Drug Trial Radar · NCT06206174
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Last checked: Nov 20, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 6, 2024
Primary completion
Feb 28, 2025
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Institute of Hematology & Blood Diseases Hospital, China
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.
Conditions
- Hematologic Malignancy
- Non Hodgkin Lymphoma
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia, Adult
- Myelodysplastic Syndromes
Interventions
TGRX-814Drug
Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximal tolerated dose (MTD)Time frame: At end of dose escalation when the probability of DLT of a dose level is greater than 0.359
- Recommended phase II dose (RP2D)Time frame: At completion of the dose escalation study, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.